The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Objective: To examine the prevalence of metabolic syndrome and its risk factors in a large group of schizophrenic patients. Methods: Sociodemographic and treatment data were collected from medical records of 1,103 inpatients and outpatients treated for schizophrenia at Seoul National Hospital in Seoul, Korea. Anthropometric measurement and blood testing were conducted for collection of physical and biochemical data and diagnosis of metabolic syndrome. Data for metabolic syndrome prevalence were compared by sex, age, metabolic syndrome markers present, treatment of markers, and types of antipsychotics and individual drug agents used. Results: Mean prevalence of metabolic syndrome in all subjects was 43.9% and 40.1% according to adapted Adult Treatment Panel III (ATP-IIIa) and International Diabetes Federation criteria, respectively. No significant differences were found in prevalence according to ATP-IIIa criteria between men (42.6%) and woman (45.9%). A trend toward higher prevalence with age was observed for both sexes until 50 years, followed by a continued increase for women but a decrease for men. Use of a combination of atypical antipsychotics was associated with the highest metabolic syndrome prevalence and use of aripiprazole with the lowest. High percentages of subjects with hypertension and dyslipidemia were not being treated for these conditions. Conclusion: Despite their higher prevalence in schizophrenic patients, metabolic syndrome and its markers are not being adequately managed in these patients. Treatment of schizophrenic patients requires attention to not only their psychiatric conditions but also associated medical conditions by individual health care practitioners and hospitals as well as the public health care sector as a whole.
Abstract
Objective: To examine the prevalence of metabolic syndrome and its risk factors in a large group of schizophrenic patients. Methods: Sociodemographic and treatment data were collected from medical records of 1,103 inpatients and outpatients treated for schizophrenia at Seoul National Hospital in Seoul, Korea. Anthropometric measurement and blood testing were conducted for collection of physical and biochemical data and diagnosis of metabolic syndrome. Data for metabolic syndrome prevalence were compared by sex, age, metabolic syndrome markers present, treatment of markers, and types of antipsychotics and individual drug agents used. Results: Mean prevalence of metabolic syndrome in all subjects was 43.9% and 40.1% according to adapted Adult Treatment Panel III (ATP-IIIa) and International Diabetes Federation criteria, respectively. No significant differences were found in prevalence according to ATP-IIIa criteria between men (42.6%) and woman (45.9%). A trend toward higher prevalence with age was observed for both sexes until 50 years, followed by a continued increase for women but a decrease for men. Use of a combination of atypical antipsychotics was associated with the highest metabolic syndrome prevalence and use of aripiprazole with the lowest. High percentages of subjects with hypertension and dyslipidemia were not being treated for these conditions. Conclusion: Despite their higher prevalence in schizophrenic patients, metabolic syndrome and its markers are not being adequately managed in these patients. Treatment of schizophrenic patients requires attention to not only their psychiatric conditions but also associated medical conditions by individual health care practitioners and hospitals as well as the public health care sector as a whole.
참고문헌 (31)
- Newman SC, "Mortality in a cohort of patients with schizophrenia: a record linkage study", Can J Psychiatry, 36, pp.239~245 (1991)
- Marder SR, "Physical health monitoring of patients with schizophrenia", Am J Psychiatry, 161, pp.1334~1349 (2004)
- Reaven GM, "Banting lecture 1988. Role of insulin resistance in human disease", Diabetes, 37, pp.1595~1607 (1988)
- Alberti KG, "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation", Diabet Med, 15, pp.539~553 (1998)
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults., "Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatmentof high blood cholesterol in adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
- "The IDF consensus worldwide definition of the metabolic syndrome" (2005)[URL]
- Inoue S, "The Asia-Pacific perspective: redefining obesity and its treatment" (2000), Health Communications Australia Pty Limit
- American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity., "Consensus development conference on antipsychotic drugs and obesity and diabetes", J Clin Psychiatry, 65, pp.267~272 (2004)
- McEvoy JP, "Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III", Schizophr Res, 80, pp.19~32 (2005)
- Araneta MR, "Type 2 diabetes and metabolic syndrome in Filipina-American women: a high-risk nonobese population", Diabetes Care, 25, pp.494~499 (2002)
- Allison DB, "The distribution of body mass index among individuals with and without schizophrenia", J Clin Psychiatry, 60, pp.215~220 (1999)
- Allison DB, "Antipsychotic-induced weight gain: a comprehensive research synthesis", Am J Psychiatry, 156, pp.1686~1696 (1999)
- Wirshing DA, "Novel antipsychotics: comparison of weight gain liabilities", J Clin Psychiatry, 60, pp.358~363 (1999)
- Allison DB, "Antipsychotic-induced weight gain: a review of the literature", J Clin Psychiatry, 62(Suppl 7), pp.22~31 (2001)
- McIntyre RS, "Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities", Can J Psychiatry, 46, pp.273~281 (2001)
- Sernyak MJ, "Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia", Am J Psychiatry, 159, pp.561~566 (2002)
- Henderson DC, "Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study", Am J Psychiatry, 157, pp.975~981 (2000)
- Lindenmayer JP, "Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics", Am J Psychiatry, 160, pp.290~296 (2003)
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus., "Report of the expert committee on the diagnosis and classification of diabetes mellitus", Diabetes Care, 26(Suppl 1), pp.S5~S20 (2003)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (1994), American Psychiatric Association
- 김동희, "무증상 성인 한국인에서 관상동맥 석회 수치의 연령 및 성별 분포와 특성: 심혈관 질환의 위험요인 및 대사 증후군과의 관계", Korean Circulation Journal, 38(1), pp.29~35 (2008), 대한심장학회
- Isomaa B, "Cardiovascular morbidity and mortality associated with the metabolic syndrome", Diabetes Care, 24, pp.683~689 (2001)
- Lim S, "Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007", Diabetes Care, 34, pp.1323~1328 (2011)
- National Institutes of Health, "Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report", Obes Res, 6(Suppl 2), pp.51S~209S (1998)
- Goldstein BJ, "Insulin resistance: from benign to type 2 diabetes mellitus", Rev Cardiovasc Med, 4(Suppl 6), pp.S3~S10 (2003)
- Nasrallah HA, "Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline", Schizophr Res, 86, pp.15~22 (2006)
- Druss BG, "Quality of medical care and excess mortality in older patients with mental disorders", Arch Gen Psychiatry, 58, pp.565~572 (2001)
- Bray GA, "Medical consequences of obesity", J Clin Endocrinol Metab, 89, pp.2583~2589 (2004)
- Grundy SM, "Obesity, metabolic syndrome, and cardiovascular disease", J Clin Endocrinol Metab, 89, pp.2595~2600 (2004)
- Meyer JM, "The effects of antipsychotic therapy on serum lipids: a comprehensive review", Schizophr Res, 70, pp.1~17 (2004)
- McQuade RD, "A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study", J Clin Psychiatry, 65(Suppl 18), pp.47~56 (2004)